Stock Events

Stock Events

FSD Pharma 

0
155
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q1 2026
Q2 2026
Next
-2.55
-1.82
-1.09
-0.36
Expected EPS
-0.4328
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-22.89MNet Income

Analyst Ratings

$6.07Average Price Target
The highest estimate is 6.07.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0K9A.STU. It's not an investment recommendation.
Amazon
13
AMZN
NVIDIA
13
NVDA
Microsoft
12
MSFT
AMD
12
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Cronos Group
CRON
Mkt Cap1.16B
Cronos Group is involved in the production and sale of cannabis and cannabis-derived products, making it a direct competitor in the cannabis market.
Tilray Brands
TLRY
Mkt Cap553.08M
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, competing in the same market as FSD Pharma.
Canopy Growth
CGC
Mkt Cap392.45M
Canopy Growth Corporation operates in the cannabis and hemp business, directly competing with FSD Pharma in the cannabis industry.
Aurora Cannabis
ACB
Mkt Cap236.78M
Aurora Cannabis is engaged in the production, distribution, and sale of cannabis products, competing in the same industry as FSD Pharma.
Green Thumb Industries
GTBIF
Mkt Cap1.56B
Green Thumb Industries is involved in the cultivation, sale, and distribution of cannabis products, making it a competitor in the cannabis industry alongside FSD Pharma.

About

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Show more...
CEO
Zeeshan Saeed
Employees
7
Country
Canada
ISIN
CA35954B2066
WKN
000A3E2LR

Listings

F
DE
0K91.F
STU
DE
0K91.STU
MU
DE
0K9.MU
STU
DE
0K9A.STU

0 Comments

Share your thoughts

FAQ

What is FSD Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange FSD Pharma stocks are traded under the ticker 0K9A.STU.
When is the next FSD Pharma earnings date?▼
FSD Pharma is going to release the next earnings report on November 06, 2026.
What were FSD Pharma earnings last quarter?▼
0K9A.STU earnings for the last quarter are -0.41 EUR per share, whereas the estimation was -0.36 EUR resulting in a -11.9% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is FSD Pharma revenue for the last year?▼
FSD Pharma revenue for the last year amounts to 0 EUR.
What is FSD Pharma net income for the last year?▼
0K9A.STU net income for the last year is -22.89M EUR.
How many employees does FSD Pharma have?▼
As of September 15, 2026, the company has 7 employees.
In which sector is FSD Pharma located?▼
FSD Pharma operates in the Health & Wellness sector.
When did FSD Pharma complete a stock split?▼
FSD Pharma has not had any recent stock splits.
Where is FSD Pharma headquartered?▼
FSD Pharma is headquartered in Toronto, Canada.